524,490 Shares in Edwards Lifesciences Corporation $EW Acquired by Danske Bank A S

Danske Bank A S bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 524,490 shares of the medical research company’s stock, valued at approximately $47,445,000. Danske Bank A S owned approximately 0.09% of Edwards Lifesciences at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of EW. Rehmann Capital Advisory Group grew its stake in Edwards Lifesciences by 2.1% in the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after buying an additional 130 shares in the last quarter. McIlrath & Eck LLC raised its position in shares of Edwards Lifesciences by 14.6% during the 4th quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock valued at $90,000 after buying an additional 135 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Edwards Lifesciences by 0.9% during the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock worth $1,288,000 after acquiring an additional 136 shares during the last quarter. Stephens Inc. AR lifted its holdings in shares of Edwards Lifesciences by 5.4% during the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock worth $239,000 after acquiring an additional 144 shares during the last quarter. Finally, Composition Wealth LLC lifted its holdings in shares of Edwards Lifesciences by 1.6% during the 4th quarter. Composition Wealth LLC now owns 9,331 shares of the medical research company’s stock worth $795,000 after acquiring an additional 147 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

EW has been the topic of a number of research analyst reports. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their target price for the company from $87.00 to $101.00 in a research note on Friday, July 24th. Robert W. Baird lifted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Mizuho upped their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Evercore reiterated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Finally, Royal Bank Of Canada increased their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Trading Up 1.5%

Shares of EW stock opened at $92.36 on Thursday. The business has a 50-day moving average of $89.03 and a 200 day moving average of $84.57. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The stock has a market capitalization of $53.18 billion, a PE ratio of 53.08, a P/E/G ratio of 2.29 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the prior year, the company posted $0.67 EPS. The firm’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 25,570 shares of company stock worth $2,219,390 over the last ninety days. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.